T1	Participants 108 146	patients with gastrointestinal cancer.
T2	Participants 417 455	patients with gastrointestinal cancer.
T3	Participants 741 818	among 512 patients with gastrointestinal cancer included in the TACTIC study.
T4	Participants 832 1006	89.2 per cent of patients had a primary tumour and 79.7 per cent underwent surgery with curative intent; 243 patients received perioperative RBC transfusion (median 3 units).
T5	Participants 1118 1126	LD group
T6	Participants 1152 1164	non-LD group
T7	Participants 1435 1473	patients with gastrointestinal cancer.
